EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes
EQS-Ad-hoc: Eckert Ziegler Strahlen- und Medizintechnik AG / Key word(s): Joint Venture Berlin, 14.11.2023. Eckert Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma). Eckert Ziegler will benefit from the cooperation between the two companies above all at its production site in Jintan near Shanghai. Here, the radioisotopes urgently needed for cancer diagnostics and therapy on the growing Chinese market shall be produced and commercialized. DC Pharma invests € 20 million in the EZAG subsidiary Qi Kang Medical Technology (Changzhou) Co., Ltd. by way of a capital increase and will subsequently hold 50% of the shares. The joint venture will complete the production facility currently under construction in Jintan and start the production of cyclotron-based isotopes in a first phase. In a second phase, further production lines for radioisotopes such as Lu-177 are to follow. DC Pharma is one of the leading radiopharmaceutical companies in China with sales of 498 million US$ or 3.6 billion CNY (2022). With its market position, experience in production and sales, it is the ideal partner for Eckert Ziegler. End of Inside Information
14-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Eckert Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | [email protected] |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1773021 |
End of Announcement | EQS News Service |
|
1773021 14-Nov-2023 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Die Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie wird von der Community stark bevorzugt: Mehrere Buy-Einschätzungen, keine Sell-Einschätzungen.
Die Community sieht für Eckert & Ziegler Strahlen- und Medizintechnik AG ein Kursziel von 95 €, was den aktuellen Kurs von 40.54 € weit übersteigt.